Article Trunk



Posts Tagged ‘disease’

As Alzheimer’s costs soar, startups like Neurotrack raise cash to diagnose and treat the disease

As studies show that early diagnosis and preventative therapies can help prevent the onset of Alzheimer’s, startups that are working to diagnose the disease earlier are gaining more attention and funding. That’s a boon to companies like Neurotrack, which closed on $21 million in new financing led by the company’s previous investor, Khosla Ventures, with ...

MyndYou partners with Mizuho to expand senior care services assessing cognitive degeneration

MyndYou, which has developed a technology to assess cognitive degeneration in senior citizens, has partnered with the Japanese company Mizuho Information & Research Institute to test the company’s product for a potential nationwide rollout later in 2019.  Starting with five cities in Japan over the course of May, MyndYou’s technology will be deployed in homes around ...

Biofourmis raises $35M to develop smarter treatments for chronic diseases

Biofourmis, a Singapore-based startup pioneering a distinctly tech-based approach to the treatment of chronic conditions, has raised a $35 million Series B round for expansion. The round was led by Sequoia India and MassMutual Ventures, the VC fund from Massachusetts Mutual Life Insurance Company. Other investors who put in include EDBI, the corporate investment arm ...

These Johns Hopkins students are slashing breast cancer biopsy costs

Over 2 million women were diagnosed with breast cancer in 2018. And while the diagnosis doesn’t have to be a death sentence for women in countries like the United States, in developing countries three times as many women die from the disease. Breast cancer survival rates range from 80% or over in North America, Sweden ...

As measles returns, Indiegogo joins other tech platforms in banning Anti-Vaccine campaigns

The last year has been the worst on record in the US for measles outbreaks since the disease was declared ‘eradicated’ in 2000. Even though vaccination rates across the country are still high, (according to the CDC) there remains some communities where disinformation campaigns which claim that ‘vaccines are dangerous’ (often called ‘anti-vaxx’ campaigns) have ...

PathAI raises $60 million for its computer vision-based pathogen detection technology

With a clinical version of PathAI‘s computer vision-based pathogen detection service still at least one year from coming to market, the diagnostic technology developer has snagged $60 million in its latest round of financing. The company’s tech is used by doctors to analyze cell samples taken from patients to determine the presence or absence of ...

Healthcare by 2028 will be doctor-directed, patient-owned and powered by visual technologies

Evan Nisselson Contributor Evan Nisselson is a partner at LDV Capital. More posts by this contributor Deep learning with synthetic data will democratize the tech industry The war over artificial intelligence will be won with visual data Visual assessment is critical to healthcare – whether that is a doctor peering down your throat as you ...

Healthcare wearables level up with new moves from Apple and Alphabet

Announcements that Apple has partnered with Aetna health insurance on a new app leveraging data from its Apple Watch and reports that Verily — one of the health-focused subsidiaries of Google‘s parent company — Alphabet, is developing a shoe that can detect weight and movement, indicate increasing momentum around using data from wearables for clinical health applications and ...

Aiming to change the way people take medicine, Lyndra Therapeutics raises $55 million

A little over two years after Lyndra Therapeutics Inc. first unveiled its technology for time-delayed drug delivery through a simple pill, the company has raised $55 million to continue developing the technology for public consumption. By creating a new kind of ultra long-acting drug delivery mechanism in pills, the company claims it can remove the ...

Up to $818 million deal between J&J and Locus Biosciences points to a new path for CRISPR therapies

The up to $818 million deal between Locus Biosciences and Janssen Pharmaceuticals (a division of Johnson & Johnson) that was announced yesterday points toward a new path for CRISPR gene editing technologies and (potentially) the whole field of microbiome-targeted therapies. Based in Research Triangle Park, N.C., Locus is commercializing research initially developed by scientists at ...